Food systems for delivering nutritious and sustainable diets: Perspectives from the global network of science academies

The triple burden of malnutrition, which encompasses undernutrition, micronutrient deficiencies and obesity, is a global challenge experienced by all nations, albeit in different forms. The Food and Nutrition Security and Agriculture (FNSA) project of the InterAcademy Partnership (IAP), a global network of over 130 academies of science and medicine, sought to determine the key challenges and opportunities for science and innovation to contribute to improved FNSA. Four parallel studies were carried out, one for each region (Africa, Europe, Asia and the Pacific and the Americas), which served as a resource for a fifth study focusing on science and policy issues that require international consideration and coordination. Addressing global food and nutrition security requires a food systems approach that considers issues pertaining both to sustainable production and sustainable consumption, to deliver healthy and nutritious diets with a minimal environmental impact. Developing a broad evidence base and building critical mass in research and innovation (scientific, social and in policy), and mobilising these resources in advising policy is critical. It is also important to integrate analysis at national, regional and global levels and focus on local-global linkages and inter-regional issues. This perspectives article discusses some of the key regional and global findings of the IAP FNSA studies, in the context of more recently available evidence on the topic.The IAP FNSA project was funded by the German Federal Ministry of Education and Research (BMBF) .https://www.elsevier.com/locate/gfshj2019Agricultural Economics, Extension and Rural Developmen

Zinc finger transcription factor ecotropic viral integration site 1 is induced by all-trans retinoic acid (ATRA) and acts as a dual modulator of the ATRA response

Ecotropic viral integration site 1 (EVI1) plays important roles in leukaemia and development, and its expression is temporally and spatially highly restricted during the latter process. Nevertheless, the only physiological agent that to date has been shown to regulate transcription of this gene in mammalian cells is all-trans retinoic acid. Here we describe the identification of a retinoic acid response element that was located in the most distal of several alternative first exons of the human EVI1 gene and was constitutively bound by canonical retinoid receptors in NTERA-2 teratocarcinoma cells. Furthermore, it was the target of negative feedback by EVI1 on the induction of its own promoter by retinoic acid. This process required a previously described transcription repression domain of EVI1. Extending its role as a modulator of the retinoic acid response, EVI1 had the opposite effect on the RARβ retinoic acid response element, whose induction by all-trans retinoic acid it enhanced through a mechanism that involved almost all of its known functional domains. Augmentation of the retinoic acid response by EVI1 was also observed for the endogenous RARβ gene. Thus, we have established EVI1 as a novel type of modulator of the retinoic acid response, which can both enhance and repress induction by this agent in a promoter-specific manner

The perspective from EASAC and FEAM on direct-to-consumer genetic testing for health-related purposes

Direct-to-consumer (DTC) genetic testing services raise scientific, regulatory and ethical questions. A report was prepared by consultation with an expert Working Group and published by the academies of science (European Academies of Science Advisory Council, EASAC) and medicine (Federation of European Academies of Medicine, FEAM). This report reviews current scientific evidence, ascertains the principles that should underpin the options for action by policy-makers, and discusses the potential for devising proportionate and flexible regulation that enables future innovation, taking account of the work of other expert groups, most notably the European Society of Human Genetics. EASAC-FEAM concluded that DTC genetic testing has little clinical value at present, and expresses especial caution in several specific respects, for example relating to testing for high penetrance, serious disorders, prenatal screening, nutrigenomic and pharmacogenetic testing. It was emphasised that regulation must be on the basis that claims about the link between genetic marker and disease are scientifically valid. Other key issues to address include quality assurance (that includes the professional interpretation of results), transparent supply of accurate information, consideration of the implications for established health services, and clarification of consent procedures for any use of data for research purposes. There are important implications: for the European Commission, in revising the Directive on In Vitro Diagnostic Medical Devices; for professional bodies, in supporting training and guideline development; for the broader research community, in generating the evidence base; and for the public health community, in improving the routine translation of research advances into clinical practice